Does EVOLOCUMAB Cause High density lipoprotein decreased? 112 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 112 reports of High density lipoprotein decreased have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.1% of all adverse event reports for EVOLOCUMAB.
112
Reports of High density lipoprotein decreased with EVOLOCUMAB
0.1%
of all EVOLOCUMAB reports
0
Deaths
3
Hospitalizations
How Dangerous Is High density lipoprotein decreased From EVOLOCUMAB?
Of the 112 reports, 3 (2.7%) required hospitalization.
Is High density lipoprotein decreased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 112 reports have been filed with the FAERS database.
What Other Side Effects Does EVOLOCUMAB Cause?
Device difficult to use (31,807)
Drug dose omission by device (23,957)
Wrong technique in product usage process (21,664)
Accidental exposure to product (16,160)
Injection site pain (9,988)
Product storage error (6,606)
Back pain (5,254)
Myalgia (5,061)
Drug dose omission (4,914)
Injection site bruising (4,409)
What Other Drugs Cause High density lipoprotein decreased?
CLOZAPINE (131)
ATORVASTATIN (102)
SOMATROPIN (80)
ROSUVASTATIN (71)
BISOPROLOL (69)
LEVOTHYROXINE (56)
METFORMIN (49)
OLANZAPINE (45)
ARIPIPRAZOLE (44)
ALIROCUMAB (41)
Which EVOLOCUMAB Alternatives Have Lower High density lipoprotein decreased Risk?
EVOLOCUMAB vs EXELON
EVOLOCUMAB vs EXEMESTANE
EVOLOCUMAB vs EXENATIDE
EVOLOCUMAB vs EXFORGE
EVOLOCUMAB vs EXJADE